The central question is no longer whether we can innovate, but whether innovation can truly reach patients in time.

Doctors at Boston’s Beth Israel share how CAR T cell therapy and other emerging immune therapies are delivering promising ...

In the rapidly moving field, questions remain regarding long-term safety, durability of remission, and the FDA’s approach to ...

The remote control doesn’t trigger the self-destruction of the CAR T cells, but simply prompts them to disengage from their cancerous targets.

A new editorial perspective was published in Volume 17 of Oncotarget on February 20, 2026, titled "CAR-T therapy: Trailblazing CAR(ing) in cancer treatment." ...

Among the most promising tools of cancer therapy, engineered immune cells known as chimeric antigen-receptor (CAR) T cells have already transformed the treatment of blood cancers. Yet, despite their ...

Among the most promising tools of cancer therapy, engineered immune cells known as chimeric antigen-receptor (CAR) T cells ...

RNA CAR T therapy Descartes‑08 targets BCMA‑positive plasma cells and delivers year‑long symptom relief in myasthenia gravis after a brief course, signaling a new era of durable treatment.

Will a world where cancer is treated with a single injection arrive? The so-called ‘in vivo CAR-T’ method, which directly alters immune cells within the body, is recently transforming the cancer ...

Investcorp, a leading global alternative investment firm, today announced that Lu Daopei Medical (“LDP”), a portfolio company of the Investcorp China Pre-IPO Healthcare Fund, has partnered with ...